Compounds > n-acetyl-n-formyl-5-methoxykynurenamine
Page last updated: 2024-09-05

n-acetyl-n-formyl-5-methoxykynurenamine and deoxycytidine

n-acetyl-n-formyl-5-methoxykynurenamine has been researched along with deoxycytidine in 1 studies

Compound Research Comparison

Studies
(n-acetyl-n-formyl-5-methoxykynurenamine)		Trials
(n-acetyl-n-formyl-5-methoxykynurenamine)		Recent Studies (post-2010)
(n-acetyl-n-formyl-5-methoxykynurenamine)		Studies
(deoxycytidine)		Trials
(deoxycytidine)		Recent Studies (post-2010) (deoxycytidine)
5501318,1604,6528,898

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonior, J; Góralska, M; Jastrzębska, M; Jaworek, J; Leja-Szpak, A; Link-Lenczowski, P; Nawrot-Porąbka, K; Pierzchalski, P1

Other Studies

1 other study(ies) available for n-acetyl-n-formyl-5-methoxykynurenamine and deoxycytidine

ArticleYear
Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1).
    Pharmacological reports : PR, 2018, Volume: 70, Issue:6

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Kynuramine; Melatonin; Pancreatic Neoplasms

2018